Delaware
|
|
001-35061
|
|
94-3253730
|
(State of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
Title of each class:
|
Trading symbol(s):
|
Name of each exchange on which registered:
|
Common Stock, $0.0025 par value
|
NPTN
|
New York Stock Exchange
|
Emerging growth company
|
☐
|
(i)
|
no disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Deloitte on any matter of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Deloitte’s satisfaction, would have caused Deloitte to make reference thereto in their reports on the consolidated financial statements for such years, and
|
(ii)
|
no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
|
(i)
|
the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements or the effectiveness of internal control over financial reporting, and neither a written report or oral advice was provided to the Company that BDO concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue,
|
(ii)
|
any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K, or
|
(iii)
|
any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.
|
Exhibit Number
|
Description
|
|
|
16.1
|
Date: March 3, 2020
|
NEOPHOTONICS CORPORATION
|
|
|
|
|
|
By:
|
/S/ ELIZABETH EBY
|
|
|
Elizabeth Eby
|
|
|
Senior Vice President, Finance and
Chief Financial Officer
|
|
|
(Principal Financial and
Accounting Officer)
|
1.
|
We are in agreement with the statements made in paragraphs one through five of Item 4.01(a).
|
2.
|
We have no basis on which to agree or disagree with other statements made therein.
|